Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
News|Articles|April 1, 2026
7 Upcoming FDA Decisions in Q2 2026 to Watch
Author(s)Sabrina Serani
Fact checked by: Andrea Eleazar, MHS
Discover the critical Q2 2026 FDA decisions for Dato-DXd in TNBC and Orca-T in blood cancers, set to transform survival outcomes and precision oncology care.
Advertisement
Advertisement
The second quarter of 2026 stands as a pivotal window for the oncology and hematology sectors, with several high-stakes FDA decisions poised to reshape the treatment landscape for complex malignancies. From novel antibody-drug conjugates to cutting-edge allogeneic T-cell immunotherapies, the upcoming regulatory rulings reflect a continued push toward precision medicine and improved survival outcomes for patients with limited options.
Related to this article
Durvalumab plus enfortumab vedotin improved EFS and OS in MIBC and will be considered for FDA approval in the fourth quarter of 2026.
Etentamig significantly improved response and survival over standard therapy in the phase 3 CERVINO trial, headlining day 3 of IMS 2026 myeloma coverage.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
FDA approves belzutifan plus lenvatinib for advanced clear cell RCC after PD-1/PD-L1 therapy, based on PFS and response rate benefit vs cabozantinib.
Advisory panel backs Galleri blood test for adults 50+, citing strong specificity, mixed sensitivity, and follow-up impacts as FDA weighs approval.
Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.
Advertisement
Advertisement